Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology

IFN-γ drives inflammatory bowel disease pathogenesis through VE-cadherin-directed vascular barrier disruption (2019) Langer V, Vivi E, Regensburger D, Winkler T, Waldner M, Rath T, Schmid B, et al. Journal article, Original article Interferon Lambda Promotes Paneth Cell Death Via STAT1 Signaling in Mice and Is Increased in Inflamed Ileal Tissues of Patients With Crohn's Disease (2019) Günther C, Ruder B, Stolzer I, Dorner H, He GW, Aden K, Strigli A, et al. Journal article Inhibiting PGGT1B Disrupts Function of RHOA, Resulting in T-cell Expression of Integrin α4β7 and Development of Colitis in Mice (2019) Lopez Posadas R, Fastancz P, Martínez-Sánchez LdC, Panteleev-Ivlev J, Thonn V, Kisseleva T, Becker LS, et al. Journal article, Original article Resolution of acute intestinal graft-versus-host disease (2019) Thiagarajan S, Neurath M, Hildner K Journal article, Review article Early Symptom Improvement With Risankizumab Treatment in Patients With Moderately to Severely Active Crohn's Disease: Analysis From a Phase 2 Study (2019) Feagan BG, Sandborn WJ, D'Haens GR, Panes J, Kaser A, Ferrante M, Louis E, et al. Conference contribution Predictors of Delayed Response to Tofacitinib: Results of the OCTAVE Open Study for Delayed Responders (2019) Regueiro M, Kinnucan JA, Ungaro R, Quirk D, Su C, Lawendy N, Fan H, et al. Conference contribution High level of EPA is associated with lower perivascular coronary attenuation as measured by coronary CTA (2019) Bittner DO, Göller M, Zopf Y, Achenbach S, Marwan M Conference contribution Antipruritic effect of bezafibrate and serum autotaxin measures in patients with primary biliary cholangitis (2019) Kremer A, Le Cleac'H A, Lemoinne S, Wolf K, De Chaisemartin L, Chollet-Martin S, Humbert L, et al. Journal article, Letter LUTATHERA (R) in first line therapy of G2 and G3 GEP-NETs (the NETTER-2 study) (2019) Ferone D, Pavel ME, Kunz P, De Herder W, Santoro P, Wegener A, Broberg P, et al. Conference contribution Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen (2019) Ruszniewski P, Cwikla J, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Thanh XMT, et al. Conference contribution